Moderna and Korean Partners Target Broad Hantavirus Vaccine With mRNA Tech
TL;DR Summary
Moderna and Korea University’s Vaccine Innovation Center have been collaborating since 2023 to create an mRNA hantavirus vaccine; early preclinical results in mice (reported in 2025) show protection, but the vaccine is not yet in humans and faces funding, regulatory, and multi-strain coverage challenges, as there is currently no licensed hantavirus vaccine and the effort aims for a broad-spectrum solution in line with pandemic‑preparedness goals.
- A New Hantavirus Vaccine Is in the Works WIRED
- Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile CNBC
- The Next Frontier for Hantavirus: Finding Vaccines and Treatments WSJ
- Moderna stock extends gains on hantavirus research Yahoo Finance
- Hantavirus Vaccines and Treatments Are in the Pipeline The New York Times
Reading Insights
Total Reads
1
Unique Readers
20
Time Saved
7 min
vs 8 min read
Condensed
96%
1,488 → 65 words
Want the full story? Read the original article
Read on WIRED